Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
ASSEMBLY BIOSCIENCES, INC. reported the year ended December 31, 2025 results: revenue $72.3 million, net income Net loss attributable to common stockholders was $6.1 million, EPS $0.55 per basic and diluted share.
- Period
- the year ended December 31, 2025
- Revenue
- $72.3 million
- Net income
- Net loss attributable to common stockholders was $6.1 million
- EPS
- $0.55 per basic and diluted share
- Result
- reported results
Exact text from the filing
Year-End 2025 Financial Results • Cash, cash equivalents and marketable securities were $248.1 million as of December 31, 2025, compared to $232.6 million as of September 30, 2025, and $112.1 million as of the year ended December 31, 2024. The company’s cash position is projected to fund operations into 2028. • Revenue from collaborative research with Gilead was $72.3 million for the year ended December 31, 2025, compared to $28.5 million in 2024. The increase reflects the increase in collaboration funding. • Research and development expenses were $64.8 million for the year ended December 31, 2025, compared to $55.9 million in 2024. The increase is largely driven by an increase in spending on the HPI program, as both ABI-1179 and ABI-5366 saw significant enrollment in their respective Phase 1b clinical studies during the current year. • General and administrative expenses were $19.6 million for the year ended December 31, 2025, compared to $18.0 million in 2024. The increase was primar
View on SEC.gov